Abilify MyCite and Tetrabenazine Tablets

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Talk to your doctor before using tetrabenazine together with ARIPiprazole. Combining these medications can increase the risk of an irregular heart rhythm that may be serious. In addition, tetrabenazine can increase the risk and severity of side effects associated with ARIPiprazole, including Parkinson-like symptoms and abnormal muscle movements. The most serious of these movement disorders is a condition known as tardive dyskinesia (TD). TD mostly involves muscles in the face, but may also involve those in the limbs. You cannot control these movements, and they may not go away even after stopping the medication. There is no treatment for TD, but symptoms may lessen or disappear over time after stopping the medication. You may be more likely to develop TD if you are elderly, especially if you are a woman, or if you have diabetes. Your risk also increases the longer you take ARIPiprazole and the more of it that you take. Let your doctor know promptly if you experience muscle spasm or movements that you can't stop or control, such as lip smacking, chewing, puckering, frowning or scowling, tongue thrusting, teeth clenching, jaw twitching, blinking, eye rolling, shaking or jerking of arms and legs, tremor, jitteriness, restlessness, pacing, and foot tapping. Other symptoms such as fever, heat intolerance, excessive sweating, stiffness, difficulty moving or swallowing, sudden dizziness, lightheadedness, fainting, and fast or pounding heartbeats should also be reported to your doctor. You should avoid activities requiring mental alertness such as driving or operating machinery until you know how these medications affect you. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR CLOSELY: Tetrabenazine causes central dopamine depletion by binding reversibly to human vesicular monoamine transporter type 2 (VMAT2) and interfering with presynaptic monoamine storage mechanisms. Coadministration of tetrabenazine in combination with neuroleptic agents or other dopamine antagonists (e.g., metoclopramide) may result in severe manifestations of dopamine deficiency. Neuroleptic malignant syndrome, hyperthermia, parkinsonism, dysphagia, akathisia and other extrapyramidal disorders have been reported during tetrabenazine therapy, either alone or in combination with neuroleptic agents.

GENERALLY AVOID: Tetrabenazine as well as many neuroleptic agents (e.g., asenapine, clozapine, droperidol, haloperidol, iloperidone, paliperidone, pimozide, phenothiazines, quetiapine, risperidone, sertindole, ziprasidone) and other dopamine antagonists (e.g., domperidone) have been associated with dose-related prolongation of the QT interval. Theoretically, the use of these agents in combination may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes, because of additive arrhythmogenic potential related to their effects on cardiac conduction. In healthy male and female subjects, a single 25 or 50 mg dose of tetrabenazine has been shown to increase QTc by an average of approximately 8 msec. Effects at higher exposures to either tetrabenazine or its metabolites have not been evaluated. In general, the risk of an individual agent or a combination of agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia). In addition, the extent of drug-induced QT prolongation is dependent on the particular drugs involved and dosages of the drugs.

MANAGEMENT: The use of tetrabenazine in combination with neuroleptic agents or other dopamine antagonists should preferably be avoided. When coadministration is required, patients should be instructed to notify their physician if they experience extrapyramidal symptoms such as bradykinesia, hypertonia, rigidity, restlessness, and dysphagia. Clinicians, caregivers, and family members should be apprised of the risk of neuroleptic malignant syndrome and be alert to potential signs and symptoms such as mental status changes (e.g., mutism, catatonia, stupor, coma, agitation, confusion, hallucinations, delusions), autonomic instability, restlessness, rigidity, ataxia, myoclonus, hyperreflexia, tremors, diaphoresis, elevated creatine phosphokinase levels, and hyperpyrexia. Patients should seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.

Abilify MyCite

Generic Name: aripiprazole

Brand name: Abilify MyCite, Abilify, Abilify Discmelt, Abilify Maintena, Aristada, Aristada Initio

Synonyms: Abilify Mycite

What is Abilify MyCite?

Tetrabenazine Tablets

Generic Name: tetrabenazine

Brand name: Xenazine

Synonyms: Tetrabenazine

What is Tetrabenazine Tablets?